ZA202003981B - Process for the preparation of 2-(5-methoxyisochroman-1 -yl)-4,5-dihydro-1 h-imidazole and the hydrogensulfate salt thereof - Google Patents
Process for the preparation of 2-(5-methoxyisochroman-1 -yl)-4,5-dihydro-1 h-imidazole and the hydrogensulfate salt thereofInfo
- Publication number
- ZA202003981B ZA202003981B ZA2020/03981A ZA202003981A ZA202003981B ZA 202003981 B ZA202003981 B ZA 202003981B ZA 2020/03981 A ZA2020/03981 A ZA 2020/03981A ZA 202003981 A ZA202003981 A ZA 202003981A ZA 202003981 B ZA202003981 B ZA 202003981B
- Authority
- ZA
- South Africa
- Prior art keywords
- methoxyisochroman
- dihydro
- imidazole
- preparation
- hydrogensulfate salt
- Prior art date
Links
- GHIKYGQWBRHEGU-UHFFFAOYSA-N 2-(5-methoxy-3,4-dihydro-1h-isochromen-1-yl)-4,5-dihydro-1h-imidazole Chemical compound O1CCC=2C(OC)=CC=CC=2C1C1=NCCN1 GHIKYGQWBRHEGU-UHFFFAOYSA-N 0.000 title 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/76—Benzo[c]pyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Epoxy Resins (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20176085 | 2017-12-01 | ||
| PCT/FI2018/050864 WO2019106238A1 (en) | 2017-12-01 | 2018-11-30 | Process for the preparation of 2-(5-methoxyisochroman-1 -yl)-4,5-dihydro-1 h-imidazole and the hydrogensulfate salt thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202003981B true ZA202003981B (en) | 2021-07-28 |
Family
ID=64746580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/03981A ZA202003981B (en) | 2017-12-01 | 2020-06-30 | Process for the preparation of 2-(5-methoxyisochroman-1 -yl)-4,5-dihydro-1 h-imidazole and the hydrogensulfate salt thereof |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11352346B2 (enExample) |
| EP (1) | EP3717476B1 (enExample) |
| JP (1) | JP7339946B2 (enExample) |
| KR (1) | KR102718536B1 (enExample) |
| CN (1) | CN111630049B (enExample) |
| AU (1) | AU2018376872B2 (enExample) |
| BR (1) | BR112020010617A2 (enExample) |
| CA (1) | CA3083734A1 (enExample) |
| DK (1) | DK3717476T3 (enExample) |
| ES (1) | ES2927193T3 (enExample) |
| HR (1) | HRP20221247T1 (enExample) |
| HU (1) | HUE059849T2 (enExample) |
| IL (1) | IL274931B2 (enExample) |
| LT (1) | LT3717476T (enExample) |
| PL (1) | PL3717476T3 (enExample) |
| PT (1) | PT3717476T (enExample) |
| SI (1) | SI3717476T1 (enExample) |
| WO (1) | WO2019106238A1 (enExample) |
| ZA (1) | ZA202003981B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021020935A1 (ko) | 2019-07-31 | 2021-02-04 | 현대자동차주식회사 | 차량 내부 네트워크에 대한 sdn 기반의 침입 대응 방법 및 이를 이용한 시스템 |
| AU2022236605A1 (en) * | 2021-03-19 | 2023-11-02 | Orion Corporation | Tasipimidine formulations and use thereof |
| JP2025502480A (ja) | 2022-01-24 | 2025-01-24 | オリオン コーポレーション | イソクロマン－イミダゾール構造のアルファ－２ａアドレナリン受容体アゴニストの新規な硫酸塩形 |
| AU2023215667A1 (en) | 2022-02-04 | 2024-09-12 | Orion Corporation | Novel salt forms of isochroman-imidazole structured alpha-2a adrenoceptor agonist |
| JP2025531623A (ja) | 2022-09-28 | 2025-09-22 | オリオン コーポレーション | タシピミジンおよびｃｙｐ２ｄ６阻害薬の併用療法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410562B1 (en) * | 1998-12-18 | 2002-06-25 | Eli Lilly And Company | Hypoglycemic imidazoline compounds |
| AR090557A1 (es) * | 2012-04-02 | 2014-11-19 | Orion Corp | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 |
-
2018
- 2018-11-30 KR KR1020207019100A patent/KR102718536B1/ko active Active
- 2018-11-30 AU AU2018376872A patent/AU2018376872B2/en active Active
- 2018-11-30 EP EP18822414.1A patent/EP3717476B1/en active Active
- 2018-11-30 PT PT188224141T patent/PT3717476T/pt unknown
- 2018-11-30 HR HRP20221247TT patent/HRP20221247T1/hr unknown
- 2018-11-30 PL PL18822414.1T patent/PL3717476T3/pl unknown
- 2018-11-30 ES ES18822414T patent/ES2927193T3/es active Active
- 2018-11-30 BR BR112020010617-8A patent/BR112020010617A2/pt unknown
- 2018-11-30 CA CA3083734A patent/CA3083734A1/en active Pending
- 2018-11-30 DK DK18822414.1T patent/DK3717476T3/da active
- 2018-11-30 HU HUE18822414A patent/HUE059849T2/hu unknown
- 2018-11-30 CN CN201880076883.0A patent/CN111630049B/zh active Active
- 2018-11-30 WO PCT/FI2018/050864 patent/WO2019106238A1/en not_active Ceased
- 2018-11-30 US US16/768,093 patent/US11352346B2/en active Active
- 2018-11-30 JP JP2020529522A patent/JP7339946B2/ja active Active
- 2018-11-30 IL IL274931A patent/IL274931B2/en unknown
- 2018-11-30 SI SI201830738T patent/SI3717476T1/sl unknown
- 2018-11-30 LT LTEPPCT/FI2018/050864T patent/LT3717476T/lt unknown
-
2020
- 2020-06-30 ZA ZA2020/03981A patent/ZA202003981B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL274931B2 (en) | 2023-11-01 |
| US20200308152A1 (en) | 2020-10-01 |
| RU2020121597A (ru) | 2022-01-04 |
| HRP20221247T1 (hr) | 2022-12-09 |
| WO2019106238A1 (en) | 2019-06-06 |
| CN111630049B (zh) | 2023-06-20 |
| BR112020010617A2 (pt) | 2020-11-10 |
| IL274931A (en) | 2020-07-30 |
| HUE059849T2 (hu) | 2023-01-28 |
| AU2018376872A1 (en) | 2020-07-16 |
| RU2020121597A3 (enExample) | 2022-01-04 |
| CN111630049A (zh) | 2020-09-04 |
| DK3717476T3 (da) | 2022-09-05 |
| EP3717476A1 (en) | 2020-10-07 |
| JP7339946B2 (ja) | 2023-09-06 |
| KR20200095519A (ko) | 2020-08-10 |
| US11352346B2 (en) | 2022-06-07 |
| SI3717476T1 (sl) | 2022-10-28 |
| LT3717476T (lt) | 2022-09-26 |
| AU2018376872B2 (en) | 2023-12-07 |
| IL274931B1 (en) | 2023-07-01 |
| JP2021504418A (ja) | 2021-02-15 |
| ES2927193T3 (es) | 2022-11-03 |
| PL3717476T3 (pl) | 2022-11-21 |
| KR102718536B1 (ko) | 2024-10-21 |
| PT3717476T (pt) | 2022-08-23 |
| CA3083734A1 (en) | 2019-06-06 |
| EP3717476B1 (en) | 2022-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202003981B (en) | Process for the preparation of 2-(5-methoxyisochroman-1 -yl)-4,5-dihydro-1 h-imidazole and the hydrogensulfate salt thereof | |
| IL245882B (en) | Process for the preparation of n-[(3-aminooxetane-3-yl)methyl]-2-(1,1-dioxo-5,3-dihydro-4,1-benzothiazepine-4-yl)-6-methyl-quinazoline- 4-Amin | |
| ZA201707424B (en) | Novel 5-substituted imidazole derivatives | |
| LT3592769T (lt) | Antikūnai, atpažįstantys pd-l1 | |
| EP3373970A4 (en) | NKG2D IG FUSION PROTEIN FOR CANCER IMMUNOTHERAPY | |
| IL247833B (en) | 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-converted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation | |
| CL2016003145A1 (es) | Compuestos de [1,2,4]triazol sustituido | |
| ZA201606386B (en) | 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation | |
| PT3580219T (pt) | Processo para a preparação de remimazolam e formas de estado sólido de sais de remimazolam | |
| CL2016003175A1 (es) | Compuestos de [1, 2, 4 ] triazol e imidazol sustituidos | |
| HUE047106T2 (hu) | Eljárás gyógyászatilag alkalmazható víz elõállítására, nevezetesen injekcióhoz való vízhez (WFI), és készülék az eljárás végrehajtására | |
| EP2982378A4 (en) | COMPOSITION FOR THE PREVENTION OR TREATMENT OF SEPSIS OR SEPTIC SHOCK WITH ADK PROTEIN AS AN ACTIVE SUBSTANCE | |
| EP3400300A4 (en) | PROCESS FOR REDUCING LRRK2 EXPRESSION | |
| ZA202004349B (en) | Fluoralkenyl compounds, process for preparation and use thereof | |
| SG11202100269VA (en) | Compounds for use in the treatment of fascioliasis | |
| IL265578A (en) | 5-substituted imidazolylmethyldioxolane derivatives as fungicides | |
| IL265634A (en) | Novel 5-substituted imidazolylmethyl derivatives | |
| IL265638A (en) | 5-substituted imidazolylmethyloxirane derivatives as fungicides | |
| IL278984A (en) | Spinamide for the treatment of muscle deformity | |
| IL274560A (en) | A process for the preparation of raltagravir | |
| ZA201603729B (en) | Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine | |
| CZ32911U1 (cs) | Mobilní senzory pro síť Internetu věcí | |
| HK1233637A1 (en) | 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation | |
| HK1233636A1 (en) | 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation |